Member of the European Molecular Biology Organization (EMBO)
Alberto Bardelli spends much of his time researching Cancer research, Cancer, Colorectal cancer, KRAS and Cetuximab. The Cancer research study combines topics in areas such as Epidermal growth factor receptor, Immunology, Signal transduction, Growth factor receptor and Drug resistance. The concepts of his Cancer study are interwoven with issues in Mutation, Gene, Biopsy and Personalized medicine.
His Colorectal cancer research includes elements of Metastasis and Bioinformatics. As part of the same scientific family, Alberto Bardelli usually focuses on KRAS, concentrating on Targeted therapy and intersecting with Predictive marker and Progressive disease. His study of Panitumumab is a part of Cetuximab.
Cancer research, Colorectal cancer, Internal medicine, Oncology and Cancer are his primary areas of study. His study in Cancer research is interdisciplinary in nature, drawing from both Cancer cell, Mutation, Immunology, Kinase and Drug resistance. His Colorectal cancer study incorporates themes from Blockade, Targeted therapy and Epidermal growth factor receptor.
His Oncology study combines topics from a wide range of disciplines, such as Clinical trial, Irinotecan, Lapatinib, Biomarker and Breast cancer. His Cancer research incorporates elements of Gene, Disease, Pathology and Bioinformatics. His KRAS research includes themes of Mutant and PTEN.
His primary areas of study are Colorectal cancer, Cancer research, Internal medicine, Oncology and Cancer. Alberto Bardelli is involved in the study of Colorectal cancer that focuses on KRAS in particular. His Cancer research study integrates concerns from other disciplines, such as Exome sequencing, Cancer cell, DNA repair, DNA mismatch repair and Drug resistance.
His work on Liquid biopsy, Targeted therapy, Circulating tumor DNA and Cohort study is typically connected to Clinical Practice as part of general Internal medicine study, connecting several disciplines of science. His research in Oncology intersects with topics in Clinical trial, Pertuzumab, Lapatinib, Trastuzumab and Confidence interval. His studies deal with areas such as Reprogramming, Beta, Lung and CD8 as well as Cancer.
Alberto Bardelli mostly deals with Colorectal cancer, Cancer research, Internal medicine, Oncology and Liquid biopsy. His work in the fields of Colorectal cancer, such as KRAS, intersects with other areas such as Workflow. As a member of one scientific family, he mostly works in the field of KRAS, focusing on Blockade and, on occasion, Receptor tyrosine kinase, Basal, Cell culture, Growth factor and Growth factor receptor.
His Cancer research research is multidisciplinary, incorporating perspectives in Mutation, Cancer cell, Immune checkpoint and DNA repair. Alberto Bardelli combines subjects such as Clinical trial, Young adult, Targeted therapy, Age of onset and Primary tumor with his study of Oncology. His Liquid biopsy study combines topics in areas such as Brain cancer, Cell free, DNA and Pathology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
High frequency of mutations of the PIK3CA gene in human cancers
Yardena Samuels;Zhenghe Wang;Alberto Bardelli;Natalie Silliman.
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda;Mark Sausen;Rebecca J. Leary;Isaac Kinde.
Science Translational Medicine (2014)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio;Miriam Martini;Francesca Molinari;Andrea Sartore-Bianchi.
Journal of Clinical Oncology (2008)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero.
Annals of Oncology (2016)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad;Chong Sun;Sidong Huang;Federica Di Nicolantonio.
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz;Alberto Bardelli.
Journal of Clinical Oncology (2014)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale;Rona Yaeger;Sebastijan Hobor;Elisa Scala.
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter.
Lancet Oncology (2010)
International network of cancer genome projects
Thomas J. Hudson;Thomas J. Hudson;Warwick Anderson;Axel Aretz;Anna D. Barker.
Liquid biopsy: monitoring cancer-genetics in the blood.
Emily Crowley;Federica Di Nicolantonio;Fotios Loupakis;Alberto Bardelli.
Nature Reviews Clinical Oncology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: